Role of miRNA-1245a in sarcopenia | IJGM – Dove Medical Press

Javascript is currently disabled in your browser. Several features of this site will not function whilst javascript is disabled.
open access to scientific and medical research
Monthly downloads/views
From submission to first editorial decision.
From editorial acceptance to publication.
*Business days (Mon-Fri)
The above percentage of manuscripts have been rejected in the last 12 months.
Papers Published
Open access peer-reviewed scientific and medical journals.
Learn more
Dove Medical Press is a member of the OAI.
Learn more
Bulk reprints for the pharmaceutical industry.
Learn more
We offer real benefits to our authors, including fast-track processing of papers.
Learn more
Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly.
Learn more
Back to Journals » International Journal of General Medicine » Volume 14
Potential Roles of miRNA-1245a Regulatory Networks in Sarcopenia
Authors An L , Wang Y
Received 16 August 2021
Accepted for publication 14 September 2021
Published 14 October 2021 Volume 2021:14 Pages 6807—6813
DOI https://doi.org/10.2147/IJGM.S334501
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Li An,1 Yao Wang2

1Department of Geriatrics, Zhongda Hospital Southeast University,, Nanjing City, People’s Republic of China; 2Department of Endocrine, Zhongda Hospital Southeast University, Nanjing City, People’s Republic of China

Correspondence: Yao Wang Email [email protected]

Objective: Sarcopenia is a universal problem in elderly individuals. The molecular regulatory mechanisms in sarcopenia are not well understood. In the present study, we explored a possible molecular mechanism involved in the pathogenesis of sarcopenia.
Methods: Differentially expressed genes (DEGs) were identified using the Gene Expression Omnibus (GEO) database. Signaling pathways related to these DEGs were identified by gene set enrichment analysis (GSEA). Pearson correlation was calculated for all the pairwise comparisons of gene expression values between coding genes and DEGs. Interactions between the proteins encoded by the DEGs were identified using the STRING database. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathway analyses were performed to predict the functions of the DEGs.
Results: Three differentially expressed miRNAs and 5 differentially expressed mRNAs were identified in association with DEGs. We found that miRNA-1245a expression in patients with sarcopenia was higher than that in healthy controls. The GSEA showed that many pathways, such as the JAK-STAT signaling pathway and pathways related to glioma, gap junctions, and regulation of the actin cytoskeleton, were enriched in the high-miRNA-1245a-expression group. A total of 127 miRNA-1245a-related mRNAs were identified. The GO and KEGG analyses revealed that miRNA-1245a had a strong effect on a number of fundamental biological processes, such as kinase activity, that are related to the development of sarcopenia.
Conclusion: Our analyses indicate that miRNA-1245a may be a potential key molecule in the diagnosis and treatment of sarcopenia, which provides a basis for the research of miRNA in sarcopenia.

Keywords: miRNA-1245a, sarcopenia, gene expression profiling

Due to the aging of the global population, age-related diseases, such as sarcopenia, are becoming a great concern worldwide. The overall prevalence of sarcopenia is 10% in the 60–69-year-old population, and as people age, the incidence can exceed 40% percent in people over 80 years old.1,2 More than 200 million people worldwide are expected to suffer from sarcopenia by 2050.3 The European Working Group on Sarcopenia in Older People (EWGSOP) recommended using the presence of low muscle mass and muscle strength or physical performance to develop a practical clinical definition. Sarcopenia is an age-related syndrome characterized by progressive degeneration of skeletal muscle mass and functional decline, and it is a major contributor to the risk of physical disability, poor quality of life and premature death.3 As a major cause of frailty, disability and mortality in the elderly, sarcopenia has recently received considerable attention.4,5 The potential molecular mechanisms of sarcopenia are not completely understood but appear to involve multiple pathways associated with a decline in skeletal muscle mass and function, including inflammation, protein synthesis and degradation, autophagy, impaired satellite cell activation, and mitochondrial dysfunction.6,7 Patients with sarcopenia often have metabolic diseases such as diabetes mellitus, hyperlipidemia and hypertension.8 Considering the increase of life expectancy and the growing elderly population, a steady increase in sarcopenia in the upcoming decades will become a heavy financial burden on families, society and the health care system. Many efforts have been suggested to clarify the molecular mechanisms of sarcopenia for the purpose of developing efficient prevention strategies and appropriate treatment measures. Hence, much effort has been focused on identifying and characterizing the many pathways and mechanisms underlying sarcopenia. MicroRNAs (miRNAs) are critical regulators involved in nearly all cellular processes through the post-transcriptional regulation of gene expression. miRNAs play key roles in satellite cells regulation, myogenesis induction, muscle protein homeostasis, neurodegeneration, and fat infiltration.9 Notably, their expression profiles change with age.10 miRNAs were associated with many signaling pathways, such as TGF-β/myostatin/BMP and PI3K/AKT/mTOR, which were shown to contribute to sarcopenia development.9
In the present study, RNA expression profile datasets were downloaded from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs) in patients with sarcopenia by comprehensively applying multiple bioinformatics analysis tools. The results of the gene expression analysis provide in-depth insights into the cellular and molecular mechanisms related to the development of sarcopenia.
Gene expression profiles of GSE111006 (with 32 samples), GSE111010 (with 23 samples), and GSE111016 (with 40 samples) were obtained from the GEO database. All datasets were based on the GPL16791 platform. Figure 1 depicted the workflow of this study. Raw data on RNA expression were obtained, from which reads per million data were extracted. A log2 transformation was applied to the data and normalized by the median intensity.

Figure 1 Flowchart diagram for bioinformatics analysis in this study.

Figure 1 Flowchart diagram for bioinformatics analysis in this study.
The “limma” R package was used to perform DEG analysis by comparing samples obtained from sarcopenia and healthy control groups. The Benjamini-Hochberg method was used to adjust the raw p-values to the false discovery rate (FDR).11 DEGs were identified based on the criteria of |log2FC|>1 and FDR < 0.25.
The “limma” R package was applied to calculate the Pearson correlation between the mRNAs and DEGs. An mRNA with a |correlation coefficient| > 0.6 and P < 0.01 was considered to be a DEG-related mRNA. Interactions between the proteins encoded by the DEGs were identified using the STRING database (http://string-db.org).
GSEA was used to interpret gene expression data by using GSEA software 4.1 from the Broad Institute.12 The normalized enrichment score (NES) was calculated for each gene set. Significant KEGG enrichment was determined with the criteria set as a normal P-value <0.01 and FDR <0.25.
GO and KEGG enrichment analyses were performed to reveal the functions and pathways of DEGs, respectively, using the “clusterProfiler” R package.
All statistical analyses were performed using R software (version 4.0.2). The Wilcoxon signed-rank test was performed to determine the difference in the expression of genes. P < 0.05 was considered to be statistically significant.
The first step, which was to select and retrieve all appropriate datasets, identified the differentially expressed genes (DEGs) in skeletal muscle samples obtained from patients with sarcopenia and healthy controls. The t test in the “limma” package was used to identify the DEGs, and volcano plots were generated to visualize the DEGs (Figure 2A). In total, 3 differentially expressed miRNAs and 5 differentially expressed mRNAs were identified. We found that miRNA-1245a expression in the patients with sarcopenia was higher than that in the healthy controls. A heat map and a violin plot showing the expression levels of the DEGs are shown in Figure 2B and C.

Figure 2 Analysis of differentially expressed genes (DEGs). (A) Volcano plot of the DEGs identified by integrated analysis of the GEO datasets (red dot represents upregulated gene, blue dot represents down-regulated gene). A cutoff of a 1-fold change and FDR of <0.25 were used as the threshold values to determine DEG significance. (B) The heat map shows the expression of DEGs in sarcopenia patients compared to controls (red bars represent sarcopenia population, blue bars represent healthy population). (C) Violin plot analysis was performed to compare the expression of DEGs (red represents sarcopenia population, blue represents healthy population).

Figure 2 Analysis of differentially expressed genes (DEGs). (A) Volcano plot of the DEGs identified by integrated analysis of the GEO datasets (red dot represents upregulated gene, blue dot represents down-regulated gene). A cutoff of a 1-fold change and FDR of <0.25 were used as the threshold values to determine DEG significance. (B) The heat map shows the expression of DEGs in sarcopenia patients compared to controls (red bars represent sarcopenia population, blue bars represent healthy population). (C) Violin plot analysis was performed to compare the expression of DEGs (red represents sarcopenia population, blue represents healthy population).
Patients were divided into groups of high- and low-expression miRNA-1245a to elucidate the molecular mechanism critical for the development of sarcopenia. Finally, the outcome of GSEA showed that the KEGG pathways enriched in the high-expression group included the JAK-STAT signaling pathway and pathways related to glioma, gap junctions, and regulation of the actin cytoskeleton (Figure 3).

Figure 3 GSEA plots of four gene sets that were significantly differentiated between high- and low-miRNA-1245a expression groups. The median expression of miRNA-1245a was selected as the cut-off value.

Figure 3 GSEA plots of four gene sets that were significantly differentiated between high- and low-miRNA-1245a expression groups. The median expression of miRNA-1245a was selected as the cut-off value.
We also identified miRNA-1245a-related genes by Pearson correlation analysis. There were a total of 28 miRNA-1245a-related genes that were contained in the PPI network (Figure 4A). The GO analysis showed that these genes were enriched in extrinsic components of the membrane, kinase regulator activity, and regulation of MAP kinase activity (Figure 4B). The KEGG analysis showed that the miRNA-1245a-related genes were mainly related to the chemokine signaling pathway and Fc gamma R-mediated phagocytosis (Figure 4C).

Figure 4 (A) PPI network diagram of miRNA-1245a-related genes. (B) GO analysis of miRNA-1245a-related genes. (C) KEGG analysis of miRNA-1245a-related genes.

Abbreviations: BP, biological process; CC, cellular component; MF, molecular function.

Figure 4 (A) PPI network diagram of miRNA-1245a-related genes. (B) GO analysis of miRNA-1245a-related genes. (C) KEGG analysis of miRNA-1245a-related genes.
Abbreviations: BP, biological process; CC, cellular component; MF, molecular function.
To identify more useful biomarkers in sarcopenia, bioinformatics methods were used with three profile datasets (GSE111006, GSE111010 and GSE1111016). Thirty-three sarcopenia patients and sixty-two healthy controls were enrolled in the present research. We found a total of 3 changed miRNAs, including 2 upregulated and 1 downregulated miRNAs in the patients with sarcopenia. Only miR-1245a was used to analysis as a target biomarker for sarcopenia rather than another miRNA in our study because few miRNA-related genes were identified except for miRNA-1245a by Pearson correlation analysis (data not shown). A large number of miRNAs are important regulators of age-related muscle atrophy. A more comprehensive understanding of the roles of miRNAs in sarcopenia as a whole will continue to evolve. miR-550a-3p can negatively regulate the expression of ERK1 and ERK2.13 Upregulation of miR-550a-3p in sarcopenia may lead to the downregulation of the ERK1/2 signaling pathway. A previous study showed that Hachimijiogan promoted the proliferation of C2C12 skeletal muscle cells through the ERK1/2 signaling pathway without activation of the Akt signaling pathway.14 In addition, a study showed that undercarboxylated osteocalcin enhanced myogenic differentiation via activation of the GPRC6A-ERK1/2 signaling pathway.15 Exercise training was previously shown to ameliorate the aging-related muscle changes in microstructure, mitochondria, and performance through the activation of the ERK1/2 signaling pathway.16 Therefore, in this study, we inferred that the upregulation of miRNA-550a-3p might promote the development of sarcopenia by downregulating the ERK1/2 signaling pathway. To date, no information about the biological role of miRNA-1972-1 has been reported.
It was previously shown that the expression level of miRNA-1245a was downregulated after chronic resistance exercise (RE).17 However, the role of miRNA-1245a in muscle adaptation to RE training was not elucidated. Our results revealed that KEGG pathways enriched in the group with high expression of miRNA-1245a included the JAK-STAT signaling pathway and pathways related to glioma, gap junctions, and regulation of the actin cytoskeleton, which might help explain the underlying role of miRNA-1245a. Interestingly, a previous study showed that differentially methylated genes were mainly associated with the regulation of the actin cytoskeleton, energy metabolism, and muscle function in older women with sarcopenia.18
The activity of muscle satellite cells (SCs) was shown to contribute to skeletal muscle regeneration and the maintenance of muscle mass.19 Human aging is associated with susceptibility to muscle inflammation, which contributes to the impaired regenerative capacity of skeletal muscle.20 Inhibition of JAK-STAT signaling was previously shown to result in a marked enhancement of muscle repair.21 A study showed elevated p38αβ MAPK activity in freshly isolated aged SCs compared to that in young SCs.22 Partial inhibition of p38αβ MAPK signaling was shown to restore the generation of Pax7+ cells and increase the self-renewal of aged SCs.22 Activin A was shown to induce skeletal muscle catabolism through a p38 MAPK-independent mechanism.23 Hyperhomocysteinemia was shown to inhibit the regenerative capacity of SCs through p38 MAPK signaling.22
Certain limitations of these studies should be considered. First, a small number of DEGs were identified in our analysis. In addition, a previous study showed eight miRs to be upregulated in cancer cachexia, with FDRs ranging from 0.21 to 0.22;24 this result may have been related to the selection of muscle tissues from elderly individuals as a control. If we had chosen to use data from the Genotype-Tissue Expression (GETx) database as a control, more than 1000 DEGs may have been identified. Moreover, more differentially expressed miRNAs were found between old and young skeletal muscle samples in a study by Zheng et al.25 Second, information on characteristics of the patients from which samples were obtained, such as insulin resistance, obesity, diabetes, high blood pressure, and lipid abnormalities, was not provided, which prevented us from further analyzing whether these factors played roles in miRNA-1245a expression. Third, the three GEO profile datasets were composed of samples with a variety of ethnic backgrounds. Forth, “in silico analysis” is within a matter of speculation. Therefore, more studies are warranted to perform further analysis, and further in vitro and in vivo studies are required to confirm our findings.
With aging, dysregulation of miRNA-1245a in muscle is closely associated with sarcopenia, suggesting that miRNA-1245a may be a viable diagnostic and treatment biomarker for sarcopenia.
Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
Thanks are due to Dr. Jing Wang (ORCID 0000-0001-9981-5530) for assistance with the analysis of data.
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
There is no funding to report.
The authors report no conflicts of interest in this work.
1. Shafiee G, Keshtkar A, Soltani A, et al. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017;16:21. doi:10.1186/s40200-017-0302-x
2. Melton LJ 3rd, Khosla S, Crowson CS, et al. Epidemiology of sarcopenia. J Am Geriatr Soc. 2000;48(6):625–630. doi:10.1111/j.1532-5415.2000.tb04719.x
3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–423. doi:10.1093/ageing/afq034
4. Björkman M, Jyväkorpi SK, Strandberg TE, et al. Sarcopenia indicators as predictors of functional decline and need for care among older people. J Nutr Health Aging. 2019;23(10):916–922. doi:10.1007/s12603-019-1280-0
5. Yang M, Liu Y, Zuo Y, et al. Sarcopenia for predicting falls and hospitalization in community-dwelling older adults: EWGSOP versus EWGSOP2. Sci Rep. 2019;9(1):17636. doi:10.1038/s41598-019-53522-6
6. Rong S, Wang L, Peng Z, et al. The mechanisms and treatments for sarcopenia: could exosomes be a perspective research strategy in the future? J Cachexia Sarcopenia Muscle. 2020;11(2):348–365. doi:10.1002/jcsm.12536
7. Fochi S, Giuriato G, De Simone T, et al. Regulation of microRNAs in satellite cell renewal, muscle function, sarcopenia and the role of exercise. Int J Mol Sci. 2020;21(18):6732. doi:10.3390/ijms21186732
8. Richter-Stretton GL, Fenning AS, Vella RK. Skeletal muscle – A bystander or influencer of metabolic syndrome? Diabetes Metab Syndr. 2020;14(5):867–875. doi:10.1016/j.dsx.2020.06.006
9. Yin J, Qian Z, Chen Y, et al. MicroRNA regulatory networks in the pathogenesis of sarcopenia. J Cell Mol Med. 2020;24(9):4900–4912. doi:10.1111/jcmm.15197
10. Gullett JM, Chen Z, O’Shea A, et al. MicroRNA predicts cognitive performance in healthy older adults. Neurobiol Aging. 2020;95:186–194. doi:10.1016/j.neurobiolaging.2020.07.023
11. Korthauer K, Kimes PK, Duvallet C, et al. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 2019;20(1):118. doi:10.1186/s13059-019-1716-1
12. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
13. Wan C, Wen J, Huang Y, et al. Microarray analysis of differentially expressed microRNAs in myelodysplastic syndromes. Medicine. 2020;99(27):e20904. doi:10.1097/MD.0000000000020904
14. Takeda T, Tsuiji K, Li B, et al. Proliferative effect of Hachimijiogan, a Japanese herbal medicine, in C2C12 skeletal muscle cells. Clin Interv Aging. 2015;10:445–451. doi:10.2147/CIA.S75945
15. Liu S, Gao F, Wen L, et al. Osteocalcin Induces Proliferation via Positive Activation of the PI3K/Akt, P38 MAPK Pathways and Promotes Differentiation Through Activation of the GPRC6A-ERK1/2 Pathway in C2C12 Myoblast Cells. Cell Physiol Biochem. 2017;43(3):1100–1112. doi:10.1159/000481752
16. Inoue A, Cheng XW, Huang Z, et al. Exercise restores muscle stem cell mobilization, regenerative capacity and muscle metabolic alterations via adiponectin/AdipoR1 activation in SAMP10 mice. J Cachexia Sarcopenia Muscle. 2017;8(3):370–385. doi:10.1002/jcsm.12166
17. Ogasawara R, Akimoto T, Umeno T, et al. MicroRNA expression profiling in skeletal muscle reveals different regulatory patterns in high and low responders to resistance training. Physiol Genomics. 2016;48(4):320–324. doi:10.1152/physiolgenomics.00124.2015
18. He L, Khanal P, Morse CI, et al. Differentially methylated gene patterns between age-matched sarcopenic and non-sarcopenic women. J Cachexia Sarcopenia Muscle. 2019;10(6):1295–1306. doi:10.1002/jcsm.12478
19. Bellamy LM, Joanisse S, Grubb A, et al. The acute satellite cell response and skeletal muscle hypertrophy following resistance training. PLoS One. 2014;9(10):e109739. doi:10.1371/journal.pone.0109739
20. Merritt EK, Stec MJ, Thalacker-Mercer A, et al. Heightened muscle inflammation susceptibility may impair regenerative capacity in aging humans. J Appl Physiol. 2013;115(6):937–948. doi:10.1152/japplphysiol.00019.2013
21. Price FD, von Maltzahn J, Bentzinger CF, et al. Inhibition of JAK-STAT signaling stimulates adult satellite cell function. Nat Med. 2014;20(10):1174–1181. doi:10.1038/nm.3655
22. Bernet JD, Doles JD, Hall JK, et al. p38 MAPK signaling underlies a cell-autonomous loss of stem cell self-renewal in skeletal muscle of aged mice. Nat Med. 2014;20(3):265–271. doi:10.1038/nm.3465
23. Ding H, Zhang G, Sin KW, et al. Activin A induces skeletal muscle catabolism via p38β mitogen-activated protein kinase. J Cachexia Sarcopenia Muscle. 2017;8(2):202–212. doi:10.1002/jcsm.12145
24. Narasimhan A, Ghosh S, Stretch C, et al. Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J Cachexia Sarcopenia Muscle. 2017;8(3):405–416. doi:10.1002/jcsm.12168
25. Zheng Y, Kong J, Li Q, et al. Role of miRNAs in skeletal muscle aging. Clin Interv Aging. 2018;13:2407–2419. doi:10.2147/CIA.S169202
Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
 
Contact Us     Privacy Policy     Associations & Partners     Testimonials     Terms & Conditions     Recommend this site   Top
Contact Us    Privacy Policy
© Copyright 2021    Dove Press Ltd     software development by maffey.com Web Design by Adhesion
The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC
Copyright 2017 Informa PLC. All rights reserved. This site is owned and operated by Informa PLC ( “Informa”) whose registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
In order to provide our website visitors and registered users with a service tailored to their individual preferences we use cookies to analyse visitor traffic and personalise content. You can learn about our use of cookies by reading our Privacy Policy. We also retain data in relation to our visitors and registered users for internal purposes and for sharing information with our business partners. You can learn about what data of yours we retain, how it is processed, who it is shared with and your right to have your data deleted by reading our Privacy Policy.
If you agree to our use of cookies and the contents of our Privacy Policy please click ‘accept’.

source